Inhibition of mitochondrial function induces an integrated stress response in oligodendroglia

Silva, Jillian M.; Wong, Alice; Carelli, Valerio; Cortopassi, Gino A

doi:10.1016/j.nbd.2009.02.005

Cited by 73 publications

(66 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ND6 P25L synaptosomes did display a slight but significantly greater decrease in ATP levels than control mice when partially inhibited by rotenone (9.7% less than controls; P = 0.0173) (Fig. 4C), a phenomenon previously reported for cybrid cell lines harboring LHON mtDNA mutations (19,(28)(29)(30).…”

Section: Increased Forward Electron Flow But Lack Of Reverse Electronsupporting

confidence: 75%

Mouse mtDNA mutant model of Leber hereditary optic neuropathy

Lin

Sharpley

Fan

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

206

190

View full text Add to dashboard Cite

An animal model of Leber hereditary optic neuropathy (LHON) was produced by introducing the human optic atrophy mtDNA ND6 P25L mutation into the mouse. Mice with this mutation exhibited reduction in retinal function by elecroretinogram (ERG), age-related decline in central smaller caliber optic nerve fibers with sparing of larger peripheral fibers, neuronal accumulation of abnormal mitochondria, axonal swelling, and demyelination. Mitochondrial analysis revealed partial complex I and respiration defects and increased reactive oxygen species (ROS) production, whereas synaptosome analysis revealed decreased complex I activity and increased ROS but no diminution of ATP production. Thus, LHON pathophysiology may result from oxidative stress.eber hereditary optic neuropathy (LHON), the first inherited mitochondrial (mt)DNA disease reported (1), is thought to be one of the most prevalent diseases caused by mtDNA missense mutations, having an estimated frequency of 15 in 100,000 (2). Most European LHON mutations occur in the mtDNA oxidative phosphorylation (OXPHOS) complex I (NADH:ubiquinone oxidoreductase or NADH dehydrogenase) genes, the three most common being the ND4 gene mutation at nucleotide G11778A causing an arginine 340 to histidine (R340H) substitution (1), the ND1 G3460A (A52T) mutation (3), and the ND6 T14484C (M64V) mutation (4). Milder LHON mutations are generally homoplasmic (pure mutant). In contrast, more severe mtDNA complex I ND gene mutations can cause basal ganglia degeneration presenting as dystonia or Leigh syndrome when homoplasmic but optic atrophy when heteroplasmic (mixed mutant and normal mtDNAs). Two examples of such mutations are ND6 G14459A (A72V) (5) and ND6 G14600A (P25L) (6).LHON generally presents in the second or third decade of life as acute or subacute onset of central vision loss, first in one eye and then in the other. The percentage of optic atrophy in patients varies markedly among pedigrees. Male patients are two to five times more likely to develop blindness than female patients (2), and maternal relatives who have not progressed to subacute optic atrophy can still show signs of visual impairment (7,8).In LHON, optic atrophy is associated with preferential loss of the central small-caliber optic nerve fibers of the papillomacular bundle, resulting in central scotoma but with sparing of the largercaliber peripheral fibers and retention of peripheral vision. The loss of the optic nerve fibers is attributed to the death of retinal ganglion cells (RGC) as a result of the high energy demand placed on the unmyelinated portion of the optic nerve fibers anterior to the lamina cribosa, an area associated with high mitochondrial density (2).Complex I is the largest and most intricate of the mitochondrial OXPHOS complexes. It is comprised of 45 subunits, 7 (ND1, -2, -3, -4, -4L, -5, and -6) of which are coded by the mtDNA (9). Complex I transfers electrons from NADH to ubiquinone, and the energy released from this redox reaction is coupled to pumping protons across the mitochondrial in...

show abstract

Section: Increased Forward Electron Flow But Lack Of Reverse Electronsupporting

confidence: 75%

Mouse mtDNA mutant model of Leber hereditary optic neuropathy

Lin

Sharpley

Fan

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

206

190

View full text Add to dashboard Cite

show abstract

“…This is called the cell danger hypothesis 8. Aspects of the cell danger response (CDR) are also referred to as the integrated stress response 9, 10, 11. Preclinical studies showed that the cell danger response in mice produced a treatable metabolic syndrome that was maintained by purinergic signaling.…”

Section: Introductionmentioning

confidence: 99%

Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial

Naviaux

Curtis

et al. 2017

Ann Clin Transl Neurol

View full text Add to dashboard Cite

ObjectiveNo drug is yet approved to treat the core symptoms of autism spectrum disorder (ASD). Low‐dose suramin was effective in the maternal immune activation and Fragile X mouse models of ASD. The Suramin Autism Treatment‐1 (SAT‐1) trial was a double‐blind, placebo‐controlled, translational pilot study to examine the safety and activity of low‐dose suramin in children with ASD.MethodsTen male subjects with ASD, ages 5–14 years, were matched by age, IQ, and autism severity into five pairs, then randomized to receive a single, intravenous infusion of suramin (20 mg/kg) or saline. The primary outcomes were ADOS‐2 comparison scores and Expressive One‐Word Picture Vocabulary Test (EOWPVT). Secondary outcomes were the aberrant behavior checklist, autism treatment evaluation checklist, repetitive behavior questionnaire, and clinical global impression questionnaire.ResultsBlood levels of suramin were 12 ± 1.5 μmol/L (mean ± SD) at 2 days and 1.5 ± 0.5 μmol/L after 6 weeks. The terminal half‐life was 14.7 ± 0.7 days. A self‐limited, asymptomatic rash was seen, but there were no serious adverse events. ADOS‐2 comparison scores improved by −1.6 ± 0.55 points (n = 5; 95% CI = −2.3 to −0.9; Cohen's d = 2.9; P = 0.0028) in the suramin group and did not change in the placebo group. EOWPVT scores did not change. Secondary outcomes also showed improvements in language, social interaction, and decreased restricted or repetitive behaviors.InterpretationThe safety and activity of low‐dose suramin showed promise as a novel approach to treatment of ASD in this small study.

show abstract

“…It has been reported that exposure of human glioma cells and human oligodendroglial cell line to chemical hypoxia resulted in reactive oxygen species (ROS) generation and ATP depletion (Jeong et al 2003;Silva et al 2009). Uric acid, another metabolite of inosine, can eliminate peroxynitrite and ROS which is involved in apoptosis of neurons (Spitsin and Koprowski 2008).…”

Section: Discussionmentioning

confidence: 99%

The Protective Effects of Inosine Against Chemical Hypoxia on Cultured Rat Oligodendrocytes

Yang

Zhao

et al. 2011

Cell Mol Neurobiol

View full text Add to dashboard Cite

Inosine is a purine nucleoside and is considered protective to neural cells including neurons and astrocytes against hypoxic injury. However, whether oligodendrocytes (OLs) could also be protected from hypoxia by inosine is not known. Here we investigated the effects of inosine on primarily cultured rat OLs injured by rotenone-mediated chemical hypoxia, and the mechanisms of the effects using ATP assay, MTT assay, PI-Hoechst staining, TUNEL, and immunocytochemistry. Results showed that rotenone exposure for 24 h caused cell death and impaired viability in both immature and mature OLs, while pretreatment of 10 mM inosine 30 min before rotenone administration significantly reduced cell death and improved the viability of OLs. The same concentration of inosine given 120 min after rotenone exposure also improved viability of injured mature OLs. Immunocytochemistry for nitrotyrosine and cellular ATP content examination indicated that inosine may protect OLs by providing ATP and scavenging peroxynitrite for cells. In addition, immature OLs were more susceptible to hypoxia than mature OLs; and at the similar degree of injury, inosine protected immature and mature OLs differently. Quantitative real-time PCR revealed that expression of adenosine receptors was different between these two stages of OLs. These data suggest that inosine protect OLs from hypoxic injury as an antioxidant and ATP provider, and the protective effects of inosine on OLs vary with cell differentiation, possibly due to the adenosine receptors expression profile. As OLs form myelin in the central nervous system, inosine could be used as a promising drug to treat demyelination-involved disorders.

show abstract

Inhibition of mitochondrial function induces an integrated stress response in oligodendroglia

Cited by 73 publications

References 43 publications

Mouse mtDNA mutant model of Leber hereditary optic neuropathy

Mouse mtDNA mutant model of Leber hereditary optic neuropathy

Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial

The Protective Effects of Inosine Against Chemical Hypoxia on Cultured Rat Oligodendrocytes

Contact Info

Product

Resources

About